Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
Clinical trial NCT00703326 · COMPLETED
Trial details
- NCT number
- NCT00703326
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2008-08-06
- Primary completion
- 2013-03-31
- Enrollment
- 1144
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.